STOCK TITAN

Acrivon awards CBO 130K options, 30K RSUs

Acrivon Therapeutics’ chief business officer received new stock options and restricted stock units that vest over time, increasing her equity-based compensation exposure.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported that Chief Business Officer Michaela Levin received equity-based compensation on August 31, 2026. She was granted 130,000 options to buy common stock at an exercise price of $2.09 per share, expiring August 30, 2036, and 30,000 restricted stock units

Positive

  • None.

Negative

  • None.
Insider Levin Michaela
Role Chief Business Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F2 130,000 $0.00 $0.00
Grant/Award Common Stock F1 30,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 130,000 contracts (Direct); Common Stock — 30,000 shares (Direct)
Footnotes (2)
  1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, subject to the Reporting Person's continuous service through such vesting date.
  2. F2. Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
Stock options granted 130,000 options Options to purchase Acrivon common stock granted on August 31, 2026
Option exercise price $2.09 per share Exercise price for the 130,000 stock options granted to Michaela Levin
Option expiration date August 30, 2036 Expiration of the 130,000 stock options if not earlier exercised or forfeited
Restricted stock units granted 30,000 RSUs Restricted stock units representing contingent rights to Acrivon common stock
RSU vesting date September 1, 2027 Date on which all 30,000 restricted stock units vest, subject to continuous service
Initial option vesting percentage 25% Portion of option shares that vest on September 1, 2027
Remaining option vesting period 36 monthly installments Remaining option shares vest in substantially equal monthly installments after initial vesting
Common shares held after RSU grant 30,000 shares Direct common stock position reported after the RSU grant
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date."
vesting date financial
"continuous service through such vesting date."

FAQ

What equity awards did ACRV grant to Chief Business Officer Michaela Levin?

Michaela Levin received 130,000 stock options with an exercise price of $2.09 per share and 30,000 restricted stock units, all as direct holdings, on August 31, 2026.

When do Michaela Levin’s new ACRV restricted stock units vest?

The 30,000 restricted stock units granted to Michaela Levin vest in full on September 1, 2027, subject to her continuous service through that vesting date.

What is the vesting schedule for Michaela Levin’s new ACRV stock options?

For the 130,000 stock options, 25% vest on September 1, 2027. The remaining shares vest in 36 substantially equal monthly installments, subject to her continuous service through each vesting date.

What is the exercise price and expiration date of Michaela Levin’s ACRV stock options?

The newly granted stock options to Michaela Levin have an exercise price of $2.09 per share and expire on August 30, 2036, if not earlier exercised or forfeited.

Were Michaela Levin’s ACRV equity awards made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with these equity awards to Michaela Levin.

How many ACRV shares does Michaela Levin hold after these Form 4 transactions?

After these grants, Michaela Levin directly holds 30,000 shares of common stock from restricted stock units and 130,000 stock options exercisable into common stock, subject to the stated vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levin Michaela

(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026A(1)30,000A$030,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.0908/31/2026A130,000 (2)08/30/2036Common Stock130,000$0130,000D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, subject to the Reporting Person's continuous service through such vesting date.
2. Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
/s/ Adam D. Levy, Attorney-in-Fact09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)